← All tickers

Is AIDX Worth Buying in 2026?

20/20 Biolabs, Inc. Common Stock

STOCK SERVICES-TESTING LABORATORIES Updated 2026-06-14

Here’s whether 20/20 Biolabs, Inc. Common Stock (AIDX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: RSI 49 — healthy momentum range. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-11.95% over 10 days); 3-month momentum negative (-61.5%); rising volume on a downtrend (distribution, 2.09x avg). Currently 98.1% off its 52-week high. Score: -2/7.

Ready to act on this? 📈 Trade on Webull

AIDX is trading below its 200-day MA (—) — a key warning sign the longer-term trend is under pressure. An RSI of 49.1 sits in the neutral zone — momentum is neither stretched nor exhausted. With ~4 months of trading history, the return since first available bar is -96.0%. The current 98.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 4 months ago → $404 today

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✗Above 50-day MA ($1.39)
✓Above 13-day MA ($0.89)
✓RSI(7) neutral zone (30–70) — currently 66.3
✗Positive return (-61.5%)
!Within 10% of period high (−63.3%)
Period Range $0.96
$0.78 $2.62
RSI (7) 66.3
0 · OversoldOverbought · 100

Key Metrics

Price$0.96
Period Return-61.5%
Period High$2.62
Period Low$0.78
Drawdown−63.3%
MA-13$0.89
MA-50$1.39
RSI (7)66.3
Avg Volume (30d)1.3M
vs. SPYtrailed by 72.4%

Trade AIDX

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers